Tharimmune, Inc. | WebDisclosure

BRIEF

published on 08/04/2025 at 14:05, 4 months ago

Tharimmune fait progresser des thérapies clés contre le fentanyl militarisé et l'inflammation

TH104 Tharimmune TH023 Fentanyl Administration D'anticorps Par Voie Orale
PRESS RELEASE

published on 08/04/2025 at 14:00, 4 months ago

Tharimmune Issues Comprehensive Corporate Update including Lead TH104 as Critical National Security Solution Against Weaponized Fentanyl and TH023 Poised to Revolutionize Oral Antibody Delivery
Tharimmune, Inc. strengthens operational leadership, secures $5.47 million in financing, advances TH104 for national security against Fentanyl, and pioneers oral antibody medication TH023 for inflammation. Company highlights advancements in corporate governance

Equity Financing Corporate Governance National Security Tharimmune Inc. Oral Antibody Medication
BRIEF

published on 07/24/2025 at 04:20, 4 months 12 days ago

Tharimmune annonce une offre publique de 1,74 million de dollars

Investissement Biotechnologie Actions Ordinaires Offre Publique Tharimmune
BRIEF

published on 07/24/2025 at 04:20, 4 months 12 days ago

Tharimmune Announces $1.74 Million Public Offering

Biotechnology Investment Common Stock Public Offering Tharimmune
PRESS RELEASE

published on 07/24/2025 at 04:15, 4 months 12 days ago

Tharimmune Announces Pricing of $1.74 Million Registered Direct Public Offering of Common Stock and Warrants
Tharimmune, Inc. announces pricing of registered direct public offering of $1.74 million to fund working capital. President Street Global, LLC acts as placement agent

Biotechnology Public Offering Pricing Tharimmune President Street Global
BRIEF

published on 06/17/2025 at 14:06, 5 months 17 days ago

Tharimmune renforce son équipe de direction avec des nominations clés

Biotechnologie TH104 Changements De Direction Tharimmune Contre-mesures Contre Les Opioïdes
BRIEF

published on 06/17/2025 at 14:06, 5 months 17 days ago

Tharimmune Strengthens Leadership with Key Appointments

Biotechnology Leadership Changes TH104 Tharimmune Opioid Countermeasures
PRESS RELEASE

published on 06/17/2025 at 14:01, 5 months 17 days ago

Tharimmune Announces Key Leadership Appointments Including James Gordon Liddy Joining Board of Directors
Tharimmune, Inc. announces key leadership appointments and progress on pipeline development, including lead candidate TH104 for opioid antagonist delivery in high-risk scenarios

Biotechnology TH104 Leadership Pipeline Tharimmune
BRIEF

published on 05/19/2025 at 14:06, 6 months 16 days ago

Tharimmune nomme James Gordon Liddy au poste de conseiller stratégique

TH104 Crise Des Opioïdes Tharimmune Commentaires De La FDA James Gordon Liddy
BRIEF

published on 05/19/2025 at 14:06, 6 months 16 days ago

Tharimmune Appoints James Gordon Liddy as Strategic Advisor

TH104 FDA Feedback Opioid Crisis Tharimmune James Gordon Liddy

Published on 12/05/2025 at 02:35, 6 hours 41 minutes ago

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 02:30, 6 hours 46 minutes ago

Klondike Gold Announces AGM Results
Published on 12/05/2025 at 01:00, 8 hours 16 minutes ago

BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 10 hours 11 minutes ago

BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 10 hours 16 minutes ago

NXT Energy Solutions Completes Data Acquisition for SFD Survey

View all ACCESSWIRE

Published on 12/05/2025 at 09:05, 10 minutes ago

Transforming Football: IBM and Bayer 04 Leverkusen Use AI for Superior Game Analysis
Published on 12/05/2025 at 09:00, 15 minutes ago

Original-Research: DEMIRE AG (von NuWays AG): BUY
Published on 12/05/2025 at 09:00, 16 minutes ago

SPECTRIS PLC - Removal
Published on 12/05/2025 at 09:00, 16 minutes ago

Official List Notice
Published on 12/05/2025 at 09:00, 16 minutes ago

Petershill Partners plc - Removal

View all EQS

Published on 12/05/2025 at 08:45, 31 minutes ago

Air Liquide va étendre et électrifier son unité de production d'oxygène à Shaanxi, soutenant ainsi l'engagement de la Chine à décarboner son industrie
Published on 12/05/2025 at 08:45, 31 minutes ago

Air Liquide to expand and electrify its oxygen facility in Shaanxi, supporting China’s commitment to decarbonize its industry
Published on 12/05/2025 at 08:42, 33 minutes ago

ENGIE - déclaration mensuelle du nombre total d'actions et de droits de vote composant le capital au 30 novembre 2025
Published on 12/04/2025 at 18:14, 15 hours 1 minute ago

Résiliation d'une convention conclue entre actionnaires
Published on 12/04/2025 at 18:00, 15 hours 16 minutes ago

Informations relatives au nombre total de droits de vote et d’actions composant le capital social au 28 novembre 2025

View all LES ECHOS COMFI WIRE

News